Fri, Apr 18, 2014, 1:41 PM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • hbomb57108 hbomb57108 Jan 30, 2013 7:44 PM Flag

    ASCO GU Symposium

    Biobetter on Investor Village has what I think is an interesting post on upcoming events.

    Abstract #314 sticks out to me as I'm guessing we will see some patient data for Cabo treated bladder cancer

    Here are the abstract titles for ASCO GU

    Abstract #58
    Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib.
    Paul G. Corn, MD, PhD
    Poster Board: #D13

    Abstract #314
    Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).
    Andrea B. Apolo, MD
    Poster Board: #J7

    I don't know if the February 15 think tank is part of ASCO GU, but the title leaves me interested in what KOL's current thoughts may be in advanced prostate cancer.

    Friday, February 15, 2013, Orlando, FL, 7:00 PM – 9:00 PM (Eastern Time)
    Current Clinical Controversies and Promising Therapeutic Strategies in Advanced Prostate Cancer: A Live Clinical Investigator Think Tank

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$

      "I don't know if the February 15 think tank is part of ASCO GU, but the title leaves me interested in what KOL's current thoughts may be in advanced prostate cancer."

      With the ongoing industry-wide overtures wrt bone mets management - and all recent press coverage of integral bone-health clinics cropping up within the urology community, I have the highest expectations that Cabo will play quite well into any prudent discussion on advanced PC.
      Thanks for the update, Hbomb.

      GLTA

    • Andrea Apolo is the lead investigator for the phase 2 human trial for Cabo in bladder cancer, and the wording in abstract title #314 leads me to believe the correlative studies may involve preclinical followup that includes patients in that phase 2 trial.

 
EXEL
3.29-0.03(-0.90%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
WisdomTree Investments, Inc.
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT